Pfizer's $18.58 Billion Trading Volume Lands 77th Amid Patent Lawsuit Dismissal and Stock Decline

On April 4, 2025, Pfizer's trading volume reached $18.58 billion, marking a 41.6% increase from the previous day, placing it 77th in the day's stock market rankings. However, Pfizer's stock price fell by 5.43%, marking the second consecutive day of decline, with a total decrease of 7.00% over the past two days.

GlaxoSmithKline and Pfizer have agreed to dismiss a U.S. patent lawsuit over Pfizer's RSV vaccine, Abrysvo. The lawsuit, which alleged that Pfizer's vaccine infringed on patents related to GSK's own RSV shot, Arexvy, has been dismissed with prejudice, meaning it cannot be refiled. This settlement is likely to have a significant impact on Pfizer's stock price, as it resolves a major legal dispute that has been hanging over the company for some time.

The resolution of this patent dispute is a positive development for Pfizer, as it allows the company to focus on its core business without the distraction of legal battles. However, the stock price decline suggests that investors may be concerned about the potential impact of the settlement on Pfizer's future earnings. It remains to be seen how the market will react to this news in the coming days and weeks.